Shares of Cidara Therapeutics are up 20% or 14c per share to 82c on Monday in late day trading after the company said in a release that the United Kingdom Medicines and Healthcare products Regulatory Agency or MHRA has approved REZZAYO rezafungin acetate for the treatment of invasive candidiasis in adults…Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan. The company is entitled to receive a $2.8M milestone payment from Mundipharma for the MHRA approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDTX:
- Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
- Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
- Cidara announces REZZAYO approved in EU for treatment of candidiasis in Adults
- Cidara presents new preclinical data on drug-Fc conjugate candidate
- Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
